LOGIN  |  REGISTER
Chimerix

Addus HomeCare to Participate in BofA Securities Health Care Conference 2024

May 07, 2024 | Last Trade: US$117.38 0.73 0.63

FRISCO, Texas / May 07, 2024 / Business Wire / Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, today announced that Dirk Allison, Chairman and Chief Executive Officer, Brad Bickham, President and Chief Operating Officer, and Brian Poff, Executive Vice President and Chief Financial Officer, will participate in the BofA Securities 2024 Healthcare Conference, at the Encore Hotel in Las Vegas, Nevada, on May 14-16, 2024.

In connection with the conference, there will be a live broadcast and replay of the Company’s presentation available under the Investor Relations section of the Company’s website, www.addus.com, starting at 7:20 p.m. Eastern Time / 4:20 p.m. Pacific Time on Tuesday, May 14, 2024. An online replay will also be available on the Company’s website for one month, beginning approximately one hour following the conclusion of the live broadcast.

About Addus HomeCare

Addus HomeCare is a provider of home care services that primarily include personal care services that assist with activities of daily living, as well as hospice and home health services. Addus HomeCare’s consumers are primarily persons who, without these services, are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. Addus HomeCare’s payor clients include federal, state, and local governmental agencies, managed care organizations, commercial insurers, and private individuals. Addus HomeCare currently provides home care services to over 49,000 consumers through 214 locations across 22 states. For more information, please visit www.addus.com.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB